Virtual Presentation

New Agents for the Management of Ovarian Cancer

Source: Optimizing Treatment Choices in Ovarian Cancer

New Agents for the Management of Ovarian Cancer


Faculty:

  • Bradley J. Monk, MD

CME CREDIT INFORMATION

Release Date: 05/02/08

Expiration Date: 05/01/09


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss results of recent clinical trials of monoclonal antibodies used in the clinical management of ovarian cancer
  • Describe novel agents used in the treatment of patients with ovarian cancer
  • Cite clinical trials comparing novel agents with standard chemotherapies used in the clinical management of patients with ovarian cancer

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.